Latest Pharmaceuticals News

EVE Health Group’s subsidiary Nextract has inked a pivotal two-year agreement with TeleDocs Clinic, enabling nationwide online prescribing of its upcoming erectile dysfunction and dysmenorrhea products ahead of regulatory approval.

Amplia Therapeutics has reported a rare pathological complete response in a patient from its ACCENT trial, highlighting promising potential for its drug narmafotinib in treating advanced pancreatic cancer.

Mayne Pharma has dismissed a fresh termination notice from Cosette Pharmaceuticals, reaffirming its commitment to proceed with the upcoming Scheme Meeting on 18 June 2025. The dispute centers on the validity of the Scheme Implementation Deed termination claims.

CLINUVEL Pharmaceuticals announces the full-time return of Managing Director Dr Philippe Wolgen, focusing on advancing critical product development and corporate initiatives, while Acting CEO Lachlan Hay continues until September 2025.

Island Pharmaceuticals has reported encouraging Phase 2a/b trial results for ISLA-101, demonstrating meaningful reductions in dengue viral load and symptoms in humans. The findings support further clinical development of this antiviral candidate.

Bioxyne Limited has raised its FY2025 revenue guidance to $28 million, driven by explosive growth in Australian pharmaceutical manufacturing and the upcoming commercial production of MDMA capsules. The company is also making strides in expanding its footprint across Europe.

Noxopharm’s Sofra™ technology has received promising external validation from BioRay Pharmaceutical, confirming its targeted anti-inflammatory potential and broad applicability in autoimmune disease therapies.

Botanix Pharmaceuticals has secured a US$30 million debt facility from Kreos Capital, bolstering its financial position to commercialize Sofdra™ and pursue platform expansion opportunities.

Firebrick Pharma has published its pivotal Phase 3 trial results for Nasodine nasal spray, confirming its effectiveness and safety in treating the common cold, especially when used early.

Firebrick Pharma has unexpectedly withdrawn its planned share placement, raising questions about its capital strategy amid ongoing product launches.

Algorae Pharmaceuticals has secured a significant A$318,771 R&D tax incentive rebate from the Australian Taxation Office, providing a non-dilutive cash injection to advance its AI-driven drug discovery programs.

Mayne Pharma disputes Cosette Pharmaceuticals’ attempt to terminate their acquisition agreement, with a key court hearing postponed to September and a crucial shareholder vote set for June 18.